Axsome Therapeutics, Inc. (AXSM) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Axsome Therapeutics reported revenue of $638.5M, up 65.5% from $385.7M the year before. Net income was -$183.2M (a -28.7% net margin), or -$3.68 per diluted share. Gross margin was -26.1% and operating margin was -26.1%. Operating activities generated -$93.4M of cash, leaving -$93.9M of free cash flow. At fiscal year end, Axsome Therapeutics held $689.8M in total assets against $601.5M in total liabilities, including $322.9M of cash and equivalents.
Open the full interactive Axsome Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Axsome Therapeutics Key Stats
| Share Price | $156.32 |
|---|---|
| Market Cap | $8.10B |
| Revenue YoY Growth | +65.5% |
| 52-Week Range | $121.15 – $255.17 |
| Shares Outstanding | 51.8 million (basic, 2026 Q2) |
Axsome Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $224.6M | $270.6M | $385.7M | $638.5M |
| Cost of Goods Sold | — | — | $229.8M | $502.4M | $666.3M | $805.3M |
| Gross Profit | — | — | -$5.2M | -$231.8M | -$280.6M | -$166.8M |
| Operating Income | -$99.1M | -$124.7M | -$179.8M | -$231.8M | -$280.6M | -$166.8M |
| Pre-Tax Income | -$102.9M | -$130.4M | -$187.1M | -$238.3M | -$287.1M | -$183.7M |
| Income Tax | $0 | $0 | $0 | $960,000 | $85,000 | -$530,000 |
| Net Income | -$102.9M | -$130.4M | -$187.1M | -$239.2M | -$287.2M | -$183.2M |
| Diluted EPS | -$2.77 | -$3.47 | -$4.60 | -$5.27 | -$5.99 | -$3.68 |
Axsome Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $171.0M | $196.0M | $191.2M | $218.4M |
| Net Income | -$47.2M | -$28.6M | -$64.5M | -$51.3M |
| Diluted EPS | -$0.94 | -$0.57 | -$1.26 | -$0.99 |
Axsome Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $183.9M | $86.5M | $200.8M | $386.2M | $315.4M | $322.9M |
| Current Assets | $184.0M | $86.5M | $245.6M | $504.3M | $485.1M | $589.0M |
| Total Assets | $186.1M | $87.8M | $331.5M | $588.2M | $568.5M | $689.8M |
| Current Liabilities | $23.4M | $23.1M | $96.6M | $138.9M | $230.1M | $378.8M |
| Total Long-Term Debt | $48.3M | $49.1M | $94.3M | $178.1M | $180.7M | $187.7M |
| Total Liabilities | $72.3M | $72.2M | $221.9M | $397.3M | $511.5M | $601.5M |
| Shareholders' Equity | $113.8M | $15.6M | $109.6M | $191.0M | $57.0M | $88.3M |
Axsome Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$78.5M | -$108.2M | -$116.5M | -$145.1M | -$128.4M | -$93.4M |
| Cash From Investing | -$45,891 | -$307,549 | -$53.7M | -$582,000 | -$270,000 | -$480,000 |
| Cash From Financing | $42.4M | $11.1M | $284.6M | $331.0M | $57.8M | $101.5M |
| Free Cash Flow | -$78.5M | -$108.5M | -$117.2M | -$145.7M | -$128.7M | -$93.9M |
Figures from Axsome Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Axsome Therapeutics financials page for every line item.
Axsome Therapeutics Company Profile
| Ticker | AXSM |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001579428 |
Frequently Asked Questions
What was Axsome Therapeutics' revenue in fiscal 2025?
Axsome Therapeutics (AXSM) reported revenue of $638.5M for fiscal 2025.
What is Axsome Therapeutics' annual revenue history?
Axsome Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $224.6M; 2023: $270.6M; 2024: $385.7M; 2025: $638.5M.
What was Axsome Therapeutics' net income in fiscal 2025?
Axsome Therapeutics reported net income of -$183.2M for fiscal 2025.
What was Axsome Therapeutics' earnings per share (EPS) in fiscal 2025?
Axsome Therapeutics' diluted EPS was -$3.68 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Axsome Therapeutics generate in fiscal 2025?
Axsome Therapeutics generated -$93.9M of free cash flow in fiscal 2025.
What was Axsome Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Axsome Therapeutics reported revenue of $218.4M.
How much debt does Axsome Therapeutics have?
Axsome Therapeutics reported $187.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Axsome Therapeutics are outstanding?
Axsome Therapeutics reported a weighted average of 51.8 million basic shares outstanding in 2026 Q2.
What is Axsome Therapeutics' market cap?
Based on its latest closing price, Axsome Therapeutics (AXSM) has a market capitalization of about $8.10B.
When does Axsome Therapeutics' fiscal year end?
Axsome Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Axsome Therapeutics headquartered?
Axsome Therapeutics lists its business address in New York, New York in its SEC filings.